Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 9/20 | 0.66 |
| ▸ | RXRA | P19793 | 9/20 | 0.66 |
| ▸ | RXRG | P48443 | 6/20 | 0.66 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.56 |
| ▸ | CD69 | Q07108 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PTGIR | P43119 | 5/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28548896 | 0.98 | RXRB (0.64) | RXRBRXRARXRGMRGPRX4CD69 | |
| SCHEMBL13768229 | 0.86 | RXRA (0.57) | RXRBRXRARXRGMRGPRX4HSD17B10 | |
| SCHEMBL19582253 | 0.83 | RXRB (0.48) | RXRBRXRARXRGCD69HSD17B10 | |
| SCHEMBL8546134 | 0.83 | RXRA (0.54) | RXRBRXRARXRGMRGPRX4TSHR | |
| SCHEMBL19599364 | 0.82 | ADRA2A (0.60) | RXRBRXRARXRG | |
| SCHEMBL2876699 | 0.81 | RXRA (0.54) | RXRBRXRARXRGMRGPRX4TSHR | |
| SCHEMBL28550871 | 0.80 | MRGPRX4 (0.60) | RXRBRXRARXRGMRGPRX4TSHR | |
| SCHEMBL5508804 | 0.80 | RXRA (0.54) | RXRBRXRARXRGMRGPRX4KDM4E | |
| SCHEMBL3478697 | 0.80 | RXRA (0.51) | RXRBRXRARXRGMRGPRX4TSHR | |
| SCHEMBL9719997 | 0.79 | RXRA (0.55) | RXRBRXRARXRGMRGPRX4MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163781-B2 | Bi-aryl aminotetralines | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | BOUILLOT ANNE MARIE JEANNE | 2010-05-13 | — | — | US | disclosed |
| US-20100041714-A1 | BI-ARYL AMINOTETRALINES | BLANC JEAN-BAPTISTE | 2010-02-18 | — | — | US | disclosed |
| WO-2010018113-A2 | BI-ARYL AMINOTETRALINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041760-A1 | MONOARYL AMINOTETRALINES | BLANC JEAN-BAPTISTE | 2010-02-18 | — | — | US | disclosed |
| US-4310512-A | Derivatives of acetic and propionic acids, compositions containing same and use as malodor counteractants | BUSH BOAKE ALLEN INC. (US) | 1982-01-12 | — | — | US | disclosed |
| US-4195093-A | DIURETIC AND URICOSURIC AGENTS | ALBERT ROLLAND S.A. (FR) | 1980-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041760-A1 | MONOARYL AMINOTETRALINES | HRH1, HRH4, HRH2 | RXRB 1535/4885RXRA 1767/4885RXRG 1530/4885 |
| US-20100041714-A1 | BI-ARYL AMINOTETRALINES | HRH4, HRH2, HRH1 | RXRB 471/4885RXRA 804/4885RXRG 678/4885 |
| US-20100120669-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | RXRB 2199/4885RXRA 2659/4885RXRG 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.